Celldex Therapeutics vs ImageneBio
CLDX and IMA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLDX and IMA compare
Celldex Therapeutics is the larger company, worth 57 times as much as ImageneBio ($2.2B against $39.2M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLDX | IMA |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $39.2M |
| Share price | $28.53 | $3.45 |
| Change, 1 year | 17.1% | −59.9% |
| Change, 5 years | −33.6% | −98.1% |
| Beta (5Y) | 1.31 | 1.15 |
| Employees | 198 | 15 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 14180× | – |
| P/B | 3.4× | 0.3× (better) |
| FCF yield | −11.6% | – |
| Growth | ||
| Revenue growth (TTM) | −93.9% | – |
| Revenue growth, 5Y average | −26.9% (better) | −38.6% |
| Profitability | ||
| Operating margin | −211685% | – |
| Net margin | −195609% | – |
| FCF margin | −164392% | – |
| Return on equity | −49.5% | −32.3% (better) |
| Return on invested capital | −3698% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.97 | 16.17 (better) |
| Altman Z-score | 14.17 (better) | −1.11 |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 54.9% |
| Held by insiders | 0.41% | 52.9% |
| Insider net buying, 12 months | −$121K | $78.5K (better) |
| Short interest, % of float | 12.7% | 0.86% |
Go deeper
- CLDX stock overview
- CLDX income statement
- CLDX valuation and score
- IMA stock overview
- IMA income statement
- IMA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.